Overview
Below are the details for the FACT-Cx measure:
MEASURE NAME:
Functional Assessment of Cancer Therapy – Cervix (FACT-Cx)
VERSION:
4
NUMBER OF ITEMS:
39
PATIENT POPULATION:
Cervical cancer patients 18 years and older
RECALL PERIOD:
Past 7 days
RESPONSE SCALE:
5 point Likert-type scale
DATA COLLECTION:
Paper and electronic
ADMINISTRATION:
Self-administration and interview when applicable
SUBSCALE DOMAINS:
Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, Cervical Cancer Subscale
TIME FOR COMPLETION:
10-15 minutes
SCORING:
Manual scoring template, some items are reverse scored. Subscale scores, total scores and TOI scores possible. SAS/SPSS algorithms available.
RELATED MEASURES:
Language Availability
Available translations of the FACT-Cx can be obtained by registering for permission. Users are not permitted to translate the FACT-Cx without permission from FACIT.org. Permission from FACIT.org to translate the FACT-Cx may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system.
Please contact us for more information.
Licensing
Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained.
Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use.
To license an available version of this measure for commercial or non-commercial use, please complete our registration form. All of the information provided in the form will be kept strictly confidential. For questions, please contact us.
Selected References
Ashing-Giwa, K. Enhancing physical well-being and overall quality of life among underserved Latina-American cervical cancer survivors: feasibility study. Journal of Cancer Survivorship: Research and Practice 2008; 2(3):215-223. doi: 10.1007/s11764-008-0061-2.
Chase, D., Huang, H., Wenzel, L., Cella, D., McQuellon, R., Long, H., Moore, D., & Monk, B. Quality of Life and survival in advanced cervical cancer: A Gynecologic Oncology Group Study. Gynecologic Oncology 2012; 125(2): 315-319. doi: 10.1016/j.ygyno.2012.01.047.
Long, H., Bundy, B., Grendys, E., Benda, J., McMeekin, D., Sorosky, J., Miller, D., Eaton, L. & Fiorica, J. Randomized Phase III Trial of Cisplatin With or Without Topotecan in Carcinoma of the Uterine Cervix: A Gynecologic Oncology Group Study. Journal of Clinical Oncology 2005; 23(21): 4626-4633. doi: 10.1200/JCO.2005.10.021.
Monk, B., Sill, M., McMeekin, D., Cohn, D., Ramondetta, L., Boardman, C., Benda, J., & Cella, D. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a gynecologic oncology group study. Journal of Clinical Oncology 2009; 27(28): 4649-4655. doi: 10.1200/JCO.2009.21.8909.
Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320.
Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232.
Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85.
Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191.
Related Measures